Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
- Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12. The two abstracts presented were titled: “The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis having solid tumors; implications for treating the LM tumor with anti-HER2 therapy,” and “Circulating tumor cell analysis from the cerebrospinal fluid informs early diagnosis, treatment and prognosis in leptomeningeal carcinomatosis (LMC).
- 08/14/2023
|
Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS Cancer Conference on Saturday, August 12. The abstracts were presented by Priya U. Kumthekar, MD, a United Counsel for Neurologic Subspecialties (UCNS)-certified neuro-oncologist at Northwestern University, and David Picci.
- 08/14/2023
|
Biocept Announces the Passing of Board Chair M. Faye Wilson
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and express their gratitude for her many contributions to Biocept. Ms. Wilson was appointed to Biocept's Board in 2009 and served at various times as Lead Independent Director and as Chair. Most recently, in addition to her ro.
- 07/13/2023
|
Biocept appoints Antonino Morales as president and chief executive officer
- Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Morales, who has been serving as the company's interim chief financial officer since February 2022 and as a director of the company since July 2021, will now take on the leadership role.
- 06/21/2023
|
Biocept Names Antonino Morales as President and Chief Executive Officer
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as.
- 06/20/2023
|
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept's discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch. Registration information to become an M-Vest member for access to t.
- 06/14/2023
|
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
- Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company's cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture. In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person's brain and spinal cord (the leptomeninges).
- 06/05/2023
|
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus Cytology
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CNSide--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago showing the ability of CNSide™ to detect rates of leptomeningeal metastases (LM) compared with standard CSF cytology from lumbar puncture. The poster, titled “Evaluating the diagnostic performance of leptomeningeal.
- 06/05/2023
|
Why Is Biocept (BIOC) Stock Down 42% Today?
- Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock.
- 05/25/2023
|
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share (or pre-funded warrant in lieu thereof) and an accompanying warrant t.
- 05/24/2023
|
Biocept shares to commence trading on split-adjusted basis
- Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock will begin trading on a split-adjusted basis as of the open of the market on May 17 under Biocept's existing ticker symbol “BIOC.
- 05/17/2023
|
Biocept Announces One-for-Thirty Reverse Stock Split
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. Biocept's common stock will continue to trade under the existing trading symbol “BIOC.” As a result of the reverse stock split,.
- 05/17/2023
|
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
- Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.
- 04/17/2023
|
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
- Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metastases has been enrolled in the FORESEE clinical trial with the company's proprietary cerebrospinal fluid assay CNSide (NCT05414123). In a nutshell, leptomeningeal metastases, or LM, is cancer in your cerebrospinal fluid and membranes that surround your brain and spinal cord (the leptomeninges).
- 03/24/2023
|
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
- Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and Interim President and Chief Executive Officer Antonino Morales - Interim Chief Financial Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode.
- 11/28/2022
|
Biocept reports 176% year-over-year jump in orders for CNSide assay
- Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines.
- 11/21/2022
|
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
- Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the audit committee. This increases board membership to eight for the San Diego-based provider of molecular diagnostic assays, products and services.
- 11/18/2022
|
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
- Biocept Inc (NASDAQ:BIOC) said it is participating in a study evaluating biomarkers associated with central nervous system (CNS) metastasis in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. The study will look at cerebrospinal fluid tumor and the immune cell microenvironment to better understand treatment response, prognosis, and treatment resistance that may improve the management of CNS disease in patients with metastatic breast cancer, the company said.
- 11/16/2022
|
Biocept continuing to position itself as 'leader in neurological tumor diagnostics' as it posts second quarter results
- Biocept Inc (NASDAQ:BIOC) told investors it was continuing to position itself as a "leader in neurological tumor diagnostics" as the company released second-quarter results, which included the first revenue from a biopharma firm using its CNSide in a clinical trial. Biocept's CNSide cerebrospinal fluid assay can detect cancer cells that have metastasized to the central nervous system.
- 11/11/2022
|
Biocept expands availability of its CNSide assay for most cancers that metastasize to the central nervous system
- Biocept Inc (NASDAQ:BIOC) revealed that it has expanded the commercial availability of CNSide, which is based on its proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets, to patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, the San Diego, California-based company's CNSide is a proprietary cerebrospinal fluid (CSF) assay designed to better detect metastatic cancers involving the central nervous system (CNS).
- 10/17/2022
|
Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial
- Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord. Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).
- 06/22/2022
|
Biocept to Hold Business Strategy Conference Call Today
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up t
- 06/07/2022
|
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
- Biocept Inc (NASDAQ:BIOC) posted first-quarter results that saw its revenue jump 12% year-over-year on the back of its RT-PCR coronavirus (COVID-19) testing services. For the period ended March 31, 2022, the San Diego, California-based provider of molecular diagnostic assays, products, and services, reported revenue of $19.9 million, compared to $17.8 million in 1Q 2021.
- 05/23/2022
|
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
- Biocept, Inc. has reported a strong rise in full-year 2021 revenue due to growth in volumes for reverse transcription (RT) PCR coronavirus (COVID-19) testing. The company, a leading provider of molecular diagnostic assays, products and services, said net revenues for the year to December 31, 2021, reached $61.2 million, a 123% increase from $27.5 million in 2020.
- 04/06/2022
|
Biocept reports unaudited net revenue of $61.2 million for 2021
- Biocept Inc (NASDAQ:BIOC) has reported unaudited net revenue of $61.2 million for the financial year ending December 31, 2021. The company also said that it had cash and cash equivalents of about $28 million as of December 31, 2021 as it develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.
- 04/01/2022
|
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.
- 03/18/2022
|
Biocept outlines how its CNSide cerebrospinal fluid assay could improve treatment options for brain cancers
- Biocept Inc (NASDAQ:BIOC) (Biocept Inc (NASDAQ:BIOC)) has highlighted how its CNSide cerebrospinal fluid (CSF) assay could improve the treatment options for brain cancer patients. The biotech has been presenting at the Molecular & Precision Med Tri-Con meeting— the leading international meeting for the precision medicine community—being held in San Diego between February 21 and 23 this year.
- 02/23/2022
|
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
- Biocept Inc (NASDAQ:BIOC) announced the appointments of Samuel Riccitelli as the company's new interim CEO as well as Antonino Morales as its interim chief financial officer (CFO). Biocept also said it named M.
- 02/16/2022
|
Biocept appoints Darrell Taylor as its new chief compliance officer
- Biocept Inc (NASDAQ:BIOC) announced that it has appointed Darrell Taylor as the company's new senior vice president, general counsel and chief compliance officer. Biocept said Taylor will lead essential aspects of legal, compliance and privacy efforts, and will report to company CEO Michael Nall.
- 02/10/2022
|
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
- Biocept Inc (NASDAQ:BIOC) announced that coronavirus (COVID-19) RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant. The San Diego-based company said that it continues to serve the community with high-quality testing, having received more than 40,000 samples for COVID-19 testing since the beginning of 2022 and more than 765,000 samples since initiating this service in June 2020.
- 01/21/2022
|
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
- Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.
- 01/07/2022
|
Biocept says its CNSide assay identified HER2 and other tumor alterations in cerebrospinal fluid of patients with breast cancer and leptomeningeal disease
- Biocept Inc (NASDAQ:BIOC) said it presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD). The poster was chosen for a Spotlight Presentation at the San Antonio Breast Cancer Symposium on December 8, 2021, the company added in a statement.
- 12/09/2021
|
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
- Biocept Inc (NASDAQ:BIOC) said that it has started offering a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions. This new assay expands the company's coronavirus (COVID-19) testing program, which began in June 2020 and has now received more than 670,000 samples for processing.
- 11/22/2021
|
Biocept to present latest findings on CNSide cerebrospinal fluid assay and its use in treating breast cancer complications at Society for Neuro-Oncology annual meeting
- Biocept Inc (NASDAQ:BIOC) will present a multi-institutional case series on its CNSide cerebrospinal fluid assay at the upcoming Society for Neuro-Oncology annual meeting in Boston. The San Diego-based biotech company said it will show how CNSide helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD).
- 11/18/2021
|
Biocept is changing the way physicians examine blood work for their cancer patients and doing coronavirus testing
- Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date more than 250,000 coronavirus test samples at its San Diego lab What Biocept does: Biocept Inc (NASDAQ:BIOC) is a molecular diagnostics company focused on changing the way physicians examine blood in their patients with cancer. The San Diego-based company sells CEE-Sure blood collection tubes and has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).
- 11/16/2021
|
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
- Biocept Inc (NASDAQ:BIOC), the diagnostics-focused group, swung to a profit in its third quarter, recovering from the loss it reported in the corresponding period last year, thanks to a 165% increase in revenue on the back of increased RT-PCR COVID-19 testing. For the three months to September 30, the company posted net income of $427,000 compared to a loss of $4.9 million in 3Q, 2020.
- 11/16/2021
|
Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2021 Results - Earnings Call Transcript
- Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
Biocept says study shows its Switch-Blocker technology enhances performance of PCR-based liquid biopsy assays in detecting rare cancer mutations
- Biocept Inc (NASDAQ:BIOC) has announced the publication of a study showing that the addition of Switch-Blocker technology to common PCR-based liquid biopsy assays significantly increased sensitivity in detecting rare cancer mutations. The abstract was published in the November 2021 issue of the “Journal of Molecular Diagnostics.
- 11/09/2021
|
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
- Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10% and 30% of cancer patients, and a much higher percentage of late-stage cancer patients will develop brain or spinal cord metastasis.
- 09/29/2021
|
Biocept implements COVID-19 testing services at more than 30 community college campuses across California
- Biocept Inc has implemented its COVID-19 testing services at more than 30 community college campuses across California. Also, the company said it is streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 testing.
- 09/22/2021
|
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
- SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.
- 09/22/2021
|
7 of the Best Penny Stocks to Buy Coming Into Year-End
- These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared first on InvestorPlace.
- 09/21/2021
|
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
- SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.
- 09/21/2021
|
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees. These inducement stock options have a grant date of August 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement sto
- 08/31/2021
|
Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
- Biocept Inc (NASDAQ:BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.
- 08/19/2021
|
Biocept says a study of its cerebrospinal fluid assay CNSide shows potential use for cancer treatment
- Biocept Inc told investors that its cerebrospinal fluid assay CNSide had been shown to be able to detect markers of a complication of non-small cell lung cancer (NSCLC), which could mean targeted treatment that would allow patients' lives to be extended. More than 198,000 people are diagnosed with NSCLC each year, said Biocept, and an estimated 3-9% of those will develop leptomeningeal carcinomatosis (LMC), where the cancer spreads to the membranes surrounding the brain and spinal cord.
- 08/19/2021
|
Biocept Shares Increase Over 20% Pre-Market: Why It Happened
- The shares of Biocept Inc (NASDAQ: BIOC) increased by over 20% pre-market. This is why it happened.
- 08/19/2021
|
Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
- SAN DIEGO--(BUSINESS WIRE)--Study shows Biocept's CNSide assay detects and analyzes tumor cells in lung cancer patients, improving treatment decisions that may extend life.
- 08/19/2021
|
Biocept reports profitability for the first half on back of increased COVID-19 testing
- Biocept Inc (NASDAQ:BIOC) reported positive net income for the first half of 2021 as revenues rose due to the increased use of the firm's COVID-19 RT-PCR tests, notably in the first quarter. In the six months to June 30 this year, the diagnostics group posted a net income of $772,000 compared to a net loss of $14.8 million in the same period of 2020 on revenue of $29.8 million, a large increase from the revenue figure of $2.4 million seen in the first half of 2020.
- 08/17/2021
|
Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results - Earnings Call Transcript
- Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
Biocept appoints David Karlander as senior vice president of Commercial Operations
- Biocept Inc. said it has appointed David Karlander as senior vice president of Commercial Operations.
- 08/03/2021
|
Biocept Names David Karlander as Senior Vice President of Commercial Operations
- SAN DIEGO--(BUSINESS WIRE)--Biocept Names David Karlander Senior Vice President of Commercial Operations.
- 08/03/2021
|
Medicare Issues Coverage Determination For Biocept's Target Selector Assay For Breast Cancer
- Biocept Inc (NASDAQ: BIOC) received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). Reimbursement decision expands access to testing used to provide information to guide targeted treatment options for patients with breast cancer.
- 07/21/2021
|
Biocept wins approval for expanded Medicare coverage for its Target Selector assay to detect cancer biomarkers
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) said it has received a positive final Local Coverage Determination (LCD) from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program (MolDx), which will expand Medicare coverage for use of Biocept's Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). The company said the reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer.
- 07/21/2021
|
Medicare Issues Local Coverage Determination for Biocept's Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
- SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.
- 07/21/2021
|
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) has expanded its board of directors to nine members from seven and named director since 2020 Samuel D Riccitelli as the company's new chairman as the diagnostics group builds on recent momentum. Experienced financial executives Linda Rubinstein and Antonino Morales become new directors with immediate effect.
- 07/20/2021
|
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
- SAN DIEGO--(BUSINESS WIRE)--Biocept appointed Linda Rubinstein and Antonino Morales to its Board of Directors, and named Director Samuel D. Riccitelli as Chairman of the Board.
- 07/20/2021
|
Biocept joins the Russell Microcap Index
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced that it was added to the Russell Microcap Index as the US market opened on June 28, 2021. The Russell Microcap Index is a broadly used performance benchmark for smaller growth stocks in the US.
- 06/28/2021
|
Biocept Joins the Russell Microcap® Index
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Russell_Microcap_Index--Biocept joins the Russell Microcap Index
- 06/28/2021
|
Biocept partners with Quest Diagnostics to provide its Target Selector NGS-based liquid biopsy testing for lung cancer
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) has announced a collaboration with Quest Diagnostics Inc (NYSE:DGX) (FRA:QDI) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel. Biocept said both companies expect the service to be available to Quest's providers and patients in the fourth quarter of 2021.
- 06/22/2021
|
Wall Street takes a turn for the worse as investors eye Fed
- 12:15pm: The Dow was down 161 points, 0.5%, at 34,233 at midday. The Nasdaq lost 85 points, 0.6%, to 14,088, and the S&P 500 ticked down 11 points, 0.3%, to 4,244.
- 06/15/2021
|
Biocept says it has received 420,000 coronavirus tests since June 2020; readies flu testing for the fall
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) revealed to investors that it has received more than 420,000 samples for coronavirus testing since launching the service in June 2020. The samples are processed using Biocept's RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.
- 06/15/2021
|
Biocept says it has received 240,000 coronavirus tests since June 2020; readies flu testing for the fall
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) revealed to investors that it has received more than 420,000 samples for coronavirus testing since launching the service in June 2020. The samples are processed using Biocept's RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.
- 06/15/2021
|
Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service
- SAN DIEGO--(BUSINESS WIRE)--Biocept received more than 420,000 samples for COVID-19 testing since launching service in June 2020.
- 06/15/2021
|
Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers
- SAN DIEGO--(BUSINESS WIRE)--Biocept and CLEARED4 to develop new system for tracking and managing COVID-19 testing for campuses and other facilities returning to full capacity.
- 06/09/2021
|
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees. These inducement stock options have a grant date of May 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/02/2021
|
Biocept starts 2021 on a high with a profitable 1Q on revenue of $17.8M, driven by its coronavirus tests
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) started 2021 on a high with a profitable first quarter on revenue of $17.8 million, driven primarily by its coronavirus (COVID-19) tests. For the period ended March 31, 2020, the San Diego-based company, which develops molecular diagnostic assays, posted revenue of $17.8 million, compared with $1.4 million for the first quarter of 2020.
- 05/13/2021
|
Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2021 Results - Earnings Call Transcript
- Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Biocept makes coronavirus testing available for California's 116 community colleges
- Biocept Inc (NASDAQ:BIOC) has said it is partnering with the Foundation for California Community Colleges to make coronavirus (COVID-19) testing available for the state‘s 116 community colleges and their more than 2.1 million students. Through the Foundation's CollegeBuys program, Biocept said its PCR-based COVID-19 test is now available for community colleges to purchase for students, faculty, and staff.
- 04/28/2021
|
Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
- SAN DIEGO--(BUSINESS WIRE)--Biocept to provide COVID-19 testing to California community colleges and their more than 2.1 million students through FCCC partnership.
- 04/28/2021
|
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced the full commercial launch of CNSide, the company's cerebrospinal fluid (CSF) assay designed to better detect and manage the treatment of metastatic cancers involving the central nervous system (CNS). The company said the assay, which was initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life.
- 04/21/2021
|
Biocept Announces Full Commercial Launch of CNSide™ Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer
- SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept announces full launch of CNSide, its CSF assay designed to improve the management of metastatic cancers involving the central nervous system.
- 04/21/2021
|
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples. These test samples are processed using Biocept's RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego.
- 04/14/2021
|
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
- SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
- 04/14/2021
|
Biocept: Record Revenues And Profits Support Speculative Buy
- Biocept has been hard at work processing thousands of COVID-19 tests per week. As a result, the company reported its first profitable quarter and record full-year revenues.
- 04/12/2021
|
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept's CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard of care, and has the added advantage of identifying actionable molecular t
- 04/07/2021
|
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees. These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). T
- 04/01/2021
|
Biocept to host webinar with leading neuro-oncologists to discuss its cerebrospinal fluid assay (CSF) for diagnosing and managing tumors
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. The company said its CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard-of-care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.
- 04/01/2021
|
Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept's CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard
- 04/01/2021
|
BIOC Stock Price Increased Over 15% Pre-Market: Why It Happened
- The stock price of Biocept Inc (NASDAQ: BIOC) has increased by over 15% pre-market. This is why it happened.
- 03/30/2021
|
Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2020 Results - Earnings Call Transcript
- Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2020 Results - Earnings Call Transcript
- 03/29/2021
|
Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing
- Biocept Inc (NASDAQ:BIOC) swung to a profit in its fourth-quarter thanks to its coronavirus (COVID-19) testing driving revenue to $18.5 million. For the period ended December 31, 2020, the San Diego-based firm posted a profit of $1.9 million, or $0.14 per diluted share on 13.6 million weighted-average shares outstanding, compared to a loss of $5.7 million, or $1.97 per share on 2.9 million weighted-average shares outstanding a year earlier.
- 03/29/2021
|
Biocept: Q4 Earnings Insights
- Shares of Biocept (NASDAQ:BIOC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 170.00% over the past year to $0.14, which beat the estimate of ($0.27).
- 03/29/2021
|
Biocept changing the way physicians examine blood work for their cancer patients and doing coronavirus testing
- Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date more than 250,000 coronavirus test samples at its San Diego lab What Biocept does: Biocept Inc (NASDAQ:BIOC) is a molecular diagnostics company focused on changing the way physicians examine blood in their patients with cancer. The San Diego-based company sells CEE-Sure blood collection tubes and has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).
- 03/18/2021
|
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
- Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Decipher Biosciences, Inc. What Happened: With the cancer diagnostic market expected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.
- 03/16/2021
|
Biocept to Participate in Three Virtual Investment Conferences in March
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in three upcoming virtual investment conferences: H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. Biocept will hold virtual investor meetings. Investors can request a meeting by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here. 33rd An
- 03/09/2021
|
Biocept strikes supply agreement with Aegea Biotechnologies for co-developed ultra-sensitive coronavirus detection test
- Biocept Inc (NASDAQ:BIOC) and privately held life sciences company Aegea Biotechnologies Inc have announced a supply agreement for a new PCR-based coronavirus (COVID-19) assay kit designed by Aegea and co-developed by the two companies. Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory-developed test (LDT).
- 03/02/2021
|
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
- SAN DIEGO--(BUSINESS WIRE)--Aegea Biotechnologies & Biocept enter supply agreement to validate and commercialize new COVID-19 test to help screen, manage, and evaluate patients.
- 03/02/2021
|
Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
- Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC) patients. The research will be conducted in an independent pathology laboratory setting.
- 02/23/2021
|
Biocept teams up with Protean BioDiagnostics to study Target Selector in determining EGFR mutations in tumor samples
- Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of EGFR mutations in non-small cell lung cancer (NSCLC) patients. Protean also expects to validate the analytical performance of a laboratory developed test (LDT) based on Biocept's EGFR assay test kit in accordance with the requirements of the College of American Pathologists (CAP) validation process, the company said.
- 02/23/2021
|
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept's Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
- SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.
- 02/23/2021
|
Biocept to present study showcasing its ultra-sensative Target Selector biopsy assay kits at a virtual medical conference this week
- Biocept Inc (NASDAQ:BIOC) announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from non-small cell lung cancer patients that were deemed quantity not sufficient (QNS) by traditional testing methods in a recent study. The company plans to present its findings at the virtual Molecular Med Tri-Con Virtual Conference on February 16-18 this week.
- 02/16/2021
|
Study Shows Biocept's Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects mutations in up to 50% of tissue biopsy specimens, from patients diagnosed with non-small cell lung cancer, that were deemed quantity not sufficient (QNS). The study will be presented at the Molecular Med Tri-Con Virtual Conference, Feb. 16-18, 2021. Molecular testing of biopsy specimen
- 02/16/2021
|
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 86,720 shares of its common stock to 5 new employees. These inducement stock options have a grant date of January 31, 2021, and were granted as inducements material to t
- 02/02/2021
|
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
- SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO...
- 01/04/2021
|
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted...
- 12/31/2020
|
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
- SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has entered into...
- 12/30/2020
|
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System
- SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study...
- 11/20/2020
|
Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript
- Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript
- 11/13/2020
|
Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
- SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded...
- 11/09/2020
|
Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
- SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded...
- 11/05/2020
|
Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
- SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for...
- 10/29/2020
|
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
- Teleflex (NYSE:TFX) and Viatar CTC Solutions (OTCMKTS:VRTT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends. Profitability This table compares Teleflex and Viatar CTC Solutions’ net margins, return on equity and return […]
- 10/22/2020
|
Savran Technologies Inc. Rare Cell Detection Platform Contributes to Successful Clinical Trial for Detecting Breast Cancer Recurrence
- Savran Technologies Inc. Rare Cell Detection Platform Contributes To Successful Clinical Trial
- 10/15/2020
|
Global Liquid Biopsy Market Analysis and Forecast, 2020-2030 & Implications of COVID-19 Pandemic on the Market - ResearchAndMarkets.com
|
Volume Buzz: Biocept, Inc. (NASDAQ:BIOC), Future FinTech Group Inc. (NASDAQ:FTFT) - Stocks Equity
- Biocept, Inc. (NASDAQ:BIOC) with the stream of -4.98% also noticed, India Future FinTech Group Inc. (NASDAQ:FTFT) encountered a rapid change of -3.21% in the last hour of Friday’s trading session. …
- 10/10/2020
|
Direktur CTC: Polusi plastik ancam segitiga terumbu karang
- Direktur Eksekutif Coral Triangle Center (CTC), Rili Djohani mengatakan bahwa polusi plastik, perubahan iklim, penangkapan ikan dan pariwisata yang tidak ...
- 10/07/2020
|
BrightView Acquires Commercial Tree Care, Inc.
- BrightView Acquires Commercial Tree Care, Inc. Purchase Follows Sale of BrightView Tree Company
- 10/07/2020
|
Die ISET® Technologie identifizierte bei der Anwendung auf
DLA-Produkte bei NSCLC-Patienten mehr CTC als andere Systeme
- Rarecells Diagnostics (Frankreich), ein führendes Unternehmen der Flüssigbiopsie-Branche freut sich bekanntzugeben, dass das University Medical Center of Groningen, Niederlande, Forschungsergebnisse …
- 10/06/2020
|
Liquid Biopsy Market | COVID-19 Recovery and Growth Opportunities | Technavio
- The Global Liquid Biopsy Market will grow by $ 4.02 bn during 2020-2024
- 09/24/2020
|
Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism (NASDAQ:TYME)
- Tyme has a solid product candidate in pancreatic cancer. The company has no debt, strong IP, good insider interest.
- 09/23/2020
|
Today's Hot Mover: Biocept, Inc. (NASDAQ:BIOC), Verona Pharma plc (NASDAQ:VRNA) - Stocks Equity
- Biocept, Inc. (NASDAQ:BIOC) with the stream of -6.61% also noticed, India Verona Pharma plc (NASDAQ:VRNA) encountered a rapid change of -2.02% in the last hour of Thursday’s trading session. Biocept, …
- 09/18/2020
|
CTC Global Names Enos Banda Managing Director
- Today, CTC Global announced that Enos Banda has been named Managing Director. In this newly created position, Mr. Banda will lead the development and
- 09/14/2020
|
Biocept (BIOC) Investor Presentation - Slideshow
- The following slide deck was published by Biocept, Inc. in conjunction with this event..
- 09/11/2020
|
Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
- SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with MultiPlan, Inc. to include COVID-19 testing services at a pre-negotiated price per test. MultiPlan is a healthcare cost management company offering payment integrity, network-based and analytics-based services. With the expanded agreement, Biocept’s COVID-19 testing, in addition to its liquid biopsy oncology testing services, are now accessible to consumers who have access to the PHCS and MultiPlan Networks, MultiPlan’s national primary and complementary networks. More than 1 million healthcare providers participate in MultiPlan’s networks and 60 million health plan members have access to the company’s services. “Through our agreement with MultiPlan, Biocept is able to make our COVID-19 testing services widely available,” said Biocept's President and CEO Michael Nall. “Health plan members who use MultiPlan’s networks have had access to our Target Selector™ oncology assays for the past five years, and our COVID-19 testing services are now available under this expanded agreement. We are proud to offer our COVID-19 testing services to health providers and their patients across the U.S. during the pandemic.”Biocept operates a high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego, with specialized, licensed molecular lab staff who have been trained in performing the COVID-19 testing. The Company recently implemented a cutting-edge, new online ordering system to make COVID-19 test ordering efficient for clients and streamline the front-end onboarding process within its laboratory, allowing increased testing capacity and decreased costs. To date, Biocept has provided the vast majority of COVID-19 testing results to health providers within 48 hours of receiving the specimen with an average reimbursement of approximately $100 per test. The Company believes its test performance, quality and customer service are ideal for supporting providers and maintaining compliance with state mandates.About MultiPlan MultiPlan is committed to helping healthcare payers manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, the company interprets clients’ needs and customizes innovative solutions that combine its payment integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payers in the commercial health, dental, government and property and casualty markets, and saves these companies more than $18 billion annually. MultiPlan is owned by Hellman & Friedman and other investors. For more information, visit multiplan.com.About Biocept Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. In addition, Biocept recently added COVID-19 testing to support efforts to fight the pandemic. For additional information, please visit www.biocept.com.Forward-Looking Statements Disclaimer Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the ability of our tests to provide clinically actionable information to oncologist and their patients, Biocept’s provision of COVID-19 testing through MultiPlan or otherwise, and the ability of Biocept’s platform to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at http://www.sec.gov/.Investor Contact: LHA Investor Relations Jody Cain Jcain@lhai.com 310-691-7100
- 08/19/2020
|
Aegea Biotechnologies, Inc. Announces the Issuance of U.S. Patent for Primer-Switch Nucleic Acid Probes for the Detection of Rare Genetic Events and for PCR Amplification Improvements
- Aegea Biotechnologies, Inc. (www.aegeabiotech.com, "Aegea"), a biotechnology company focusing on the development and commercialization of next generation nucleic acid and clinical diagnostic technologies, announces the issuance of US Patent 10,745,749, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for Primer-Switch technology which is useful for detecting rare genetic events and for improving real-time PCR amplification reaction as well as associated analysis methods, including next-generation sequencing (NGS). Importantly, this patented technology can also be applied to molecular diagnostic tests for SARS-CoV-2 (COVID-19, coronavirus)
- 08/19/2020
|
Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that it has been granted US Patent number: 10,745,749, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for Primer-Switch technology, which is useful for the detection of rare cell mutations using circulating tumor DNA (ctDNA) analysis through real-time PCR and associated analysis methods, including next-generation sequencing (NGS).
- 08/18/2020
|
Can Biocept Stock Soar Over 100%? 5-Star Analyst Thinks So
- While so many businesses have suffered at the hands of COVID-19, Maxim analyst Jason McCarthy believes diagnostics specialist Biocept (BIOC) has managed to turn the narrative on its head and will exit the pandemic stronger than before.That’s not say the company has been immune to the virus’ effects. Biocept’s latest quarterly report reflected COVID-19’s negative impact on the company’s oncology testing volumes. With revenue coming in at $0.92 million, the figure missed the estimates by $0.38 million and indicated a 22.7% year-over-year drop. Oncology tests were down by 16% year-over-year.But McCarthy’s claim is based on Biocept’s recent entry into the coronavirus battlefield, where Biocept has begun providing much needed testing kits.So far, Biocept has collected 11,000 samples, at a run rate of roughly 3,000 a week, while at the same time sourcing components to put together 50,000 testing kits. As each test brings in $100, the commercial opportunity is not to be sniffed at. In contrast to many companies who have reduced staff during the pandemic, Biocept has been hiring extra hands to help meet the demand.Furthermore, with fall/winter around the corner and Covid showing no signs of fading even during the summer months, the virus, McCarthy says “could be a significant revenue driver in both the near- and long-term.”Add into the mix a balance sheet of $24 million in cash, and recently strengthened by warrant exercises which should provide at least another year of operating capital, and McCarthy believes the future looks bright for this new COVID-19 diagnostics player.“While the quarter was disappointing, we anticipate COVID-19 testing to offset the decline in oncology testing in 2H20. Importantly, cancer has not 'quarantined' and we anticipate oncology testing to return, and COVID-19 testing is likely here to stay. We expect that unlike (and unfortunately so) many businesses across America, which have declined and/or shut down, Biocept could actually come out of the pandemic even better positioned in the testing space than it was before,” the 5-star analyst concluded.Accordingly, McCarthy reiterated a Buy rating on BIOC shares, and doubled his price target from $1 to $2. The potential upside from current levels is a hefty 121%. (To watch McCarthy’s track record, click here)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/17/2020
|
Biocept Announces Agreement with Healthcare Group to Provide COVID-19 Testing to Multi-State Locations
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group to provide COVID-19 testing to skilled nursing facilities. The group operates and supports more than 50 facilities in multiple states, with most located in California, the state with one of the most stringent COVID-19 testing regulations in the U.S.
- 08/13/2020
|
Biocept Reports Second Quarter 2020 Financial Results
- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, reports financial results for the three and six months ended June 30, 2020 and provides an update on its business progress.
- 08/12/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Transparency awareness group urges NERC to halt competition transmission charge - Businessday NG
- Transparency Awareness Group on Thursday urged the federal government to urgently direct the Nigerian Electricity Regulation Commission, NERC to reverse its newly approved guidelines on filing applications for competition transition charge by electricity distribution and trading licensees. The group said new guidelines issued by NERC on Monday 27 July 2020 is capable of generating serious […]
- 08/07/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Gobernador Wolf: $10.5 millones para ayudar a los centros de educación profesional y técnica a reanudar su funcionamiento
- El Gobernador Tom Wolf está destinando aproximadamente $10.5 millones de dólares a centros de educación profesional y técnica (CTC, por sus siglas en inglés)
- 08/06/2020
|
Why Biocept's Stock Is Trading Higher Today
- Biocept (NASDAQ: BIOC) shares are trading higher on Thursday after the company announced an agreement with Aegea Biotechnologies to develop new, highly sensitive PCR-based Covid-19 assay.Biocept is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cells and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors.Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.Biocept shares were trading up 25.80% at $1.12 time of publication on Thursday. The stock has a 52-week high of $1.30 and a 52-week low of 21 cents.See more from Benzinga * Why Trimble's Stock Is Trading Higher Today * Why Bluebird Bio's Stock Is Trading Higher Today * Rocket Companies Opens For Trading At IPO Price(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/06/2020
|
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
- Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
- 08/06/2020
|
Biocept Announces Agreement with Aegea Biotechnologies to Develop New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc., an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies, announce a development agreement focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus. The COVID-19 PCR assay is based on the core Switch-Blocker technology used in Biocept's suite of ultra-sensitive oncology-focused assays. The collaboration will leverage Biocept's experience in developing high-performance assays based on the Switch-Blocker technology.
- 08/06/2020
|
Canadian Tire : Reports Second Quarter 2020 Results | MarketScreener
|
Biocept: Watch Out for This New Player in COVID-19 Testing
- The battle to extinguish the coronavirus is nowhere near the end. Cases have yet to be bought under control in many states. California is among the worst hit; Last week a new single-day death record was set, and the state’s reopening has been rolled back.Apart from the obvious need to contain the virus’ spread, comes the need for as much testing as possible.Diagnostics specialist Biocept (BIOC) has risen to the challenge. Being San Diego based, the small cap is perfectly located to meet demand in the Golden State.Over 100,000 tests are conducted each day in California. Although cases have modestly declined over the past week, the positivity rate is still over 6%, which is higher than the WHO’s 5% threshold for sufficient testing and indicates the need for additional tests.Maxim analyst Jason McCarthy notes that in addition to being able to provide the much needed testing kits, the venture should prove beneficial to Biocept’s balance sheet.“Biocept is working to increase its testing supply which comes at a key time as the US is facing a testing bottleneck with tests taking as long as 7 days to turnaround,” said the 5-star analyst, “COVID-19 is looking like it could drive growth for Biocept which we have pointed towards in prior notes. The company likely generated ~$700k since late June, and has been testing an increasing number of specimens each week, which should place them on track to offset slowed revenues around oncology testing due to the pandemic and potentially even drive growth.”Biocept has already received over 7,000 COVID-19 testing samples. The $700,000 McCarthy points out are on account of a $100 Medicare reimbursement for each test.Over 12,000 collection kits have been sent out since distribution begin in late June. Biocept has another 18,000 tests ready to go and has ordered components to produce another 20,000 collection kits. Based on present collection kit inventory, Biocept could boost the balance sheet by an additional $2.3 million.Accordingly, McCarthy rates Biocept a Buy along with a $1 price target. This figure implies 12-month upside of 12% from current levels. (To watch McCarthy’s track record, click here)Over the past 3 months, only one other analyst has posted a review of Biocept’s prospects. The additional Buy provides the diagnostics specialist with a Moderate Buy consensus rating. Investors could pocket a 71% gain, should the $1.53 average price target be met in the year ahead. (See Biocept stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/05/2020
|
Canadian Tire (TSX:CTC.A) Stock Could Bounce Back Massively Next Year!
- Canadian Tire (TSX:CTC.A) stock could bounce back once the COVID-19 pandemic is over.
- 08/05/2020
|
Coronavirus update: Global death toll tops 700,000 with 18.5 million confirmed cases and U.S. accounts for more than a quarter
- The number of confirmed deaths across the globe from the coronavirus illness COVID-19 climbed above 700,000 on Wednesday, according to data aggregated by...
- 08/05/2020
|
LD Micro - Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Angle PLC Announces Notice of AGM and Posting of Annual Report | | IT Business Net
- GUILDFORD, SURREY / ACCESSWIRE / August 5, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its Annual General Meeting (AGM) will be held at 2:00 pm on Th
- 08/05/2020
|
Acadia Healthcare looks to add services on COVID-19's 'mental and emotional toll'
- Shares of Acadia Healthcare Co. Inc. undefined fell nearly 6% in the extended session Tuesday after the company reported second-quarter revenue below Wall...
- 08/04/2020
|
Election 2020: Trump vs. Biden on tax policy
- Top 10 Firm Crowe has put together an at-a-glance guide to the candidates' positions on individual taxes.
- 08/04/2020
|
Group urges FG, NASS to stop NERC on new guidelines
- The federal government has been advised to urgently prevail on the authority of Nigerian Electricity Regulation Commission, (NERC) to reverse its newly approved guidelines on filing applications for competition transition charge by electricity distribution and trading licensees.
- 08/04/2020
|
Acadia Healthcare Reports Second Quarter 2020 Results
- Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2020. The Company reported reve
- 08/04/2020
|
Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has received more than 7,000 and processed more than 6,500 COVID-19 specimens to date using RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular lab. The Company has distributed nearly 12,000 COVID-19 PCR specimen collection kits to date, and has approximately 18,000 additional collection kits assembled and available for immediate distribution. The vast majority of COVID-19 test results were reported to healthcare providers within 48 hours of receipt of the specimen.
- 08/03/2020
|
Discos List Terms for FG's Foresic Audit | BizWatchNigeria.Ng
- Ten out of the 11 electricity distribution companies (Discos) in Nigeria’s power sector have said that they will take part in a planned forensic audit...
- 08/03/2020
|
7 Penny Stocks Worth the Danger as Pandemic Catalyzes Growth
- Investing in penny stocks is primarily the domain of highly risk-averse market participants. The risk profile of penny stocks is, of course, a double-edged sword: investors could lose a lot of money on them, yet could also reap massive returns. Many investors do consider penny stock purchases, but there are significant differences between trading them and higher-priced stocks. We reached out to Finance Professor Andrei Simonov at the Eli Broad College of Business at Michigan State University. We wanted to know whether he believes penny stocks to be a worthwhile investment, or if they are simply too risky to merit a position within one's respective portfolio. Simonov wrote:InvestorPlace - Stock Market News, Stock Advice & Trading TipsBy 'Penny Stocks', different people understand different things. Mostly, it is the term used for "microcaps" or "nanocaps" sometimes not listed on any national exchange, mostly illiquid with high trading cost (Bid-Ask Spread) and high price impact of the trade. That would be OK, but in many cases, this is paired with a lack of verifiable fundamental information. That makes Penny Stocks prone to manipulation and different kinds of fraud. I believe that most small individual investors should avoid those stocks. However, there are other examples. In 2009, Citigroup was formally a penny stock. Granted, it was a highly speculative investment at a time. But "fallen angels" like that are worth looking at.Professor Simonov clearly falls nearer the conservative end of the investor spectrum, which is understandable given his position. It's true that penny stocks often lack the transparency and long financial track records of large-cap stocks. And yes, penny stocks will remain subject to unscrupulous businessmen who maliciously issue penny stocks with fraudulent intent. Thus, investors do need to tread carefully and conduct as much due diligence as possible in this asset class. With common sense and due diligence penny stock investors can succeed.Volatility is high across markets. Interest rates are low. Investors are facing risk no matter where they look, and the investment landscape isn't what it was a few years ago. It may be time to give penny stocks another look. Nevertheless, there are not only 'fallen angels' as Simonov suggests, but also emerging champions within the sector also worthy of investor speculation. For the risk-averse investor here is a list of seven penny stocks worth the risk: * Boxlight Corporation (NASDAQ:BOXL) * Biocept Inc. (NASDAQ:BIOC) * Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) * eMagin Corporation (NYSEAMERICAN:EMAN) * Lynas Corporation Limited (ASX:LYC) * Ucore Rare Metals Inc (OTCQX:UURAF) * Byrna Technologies (CNSX:BYRN) * 7 Dividend Stocks to Buy for Beginners to Income Investing Bear in mind that these stocks all have catalysts making them worth a look. In many cases, a single macroeconomic catalyst alone will trump all other factors when evaluating penny stocks. For example, the stock of a company that benefits from a new federal mandate may provide massive returns after years of lackluster performance. Therefore, an appetite for risk, some luck, and calculated hedging of bets can equate to massive windfalls in penny stocks. Boxlight Corporation (BOXL)Source: Shutterstock Education is undergoing a big transformation around the world. And technology has been the darling of the pandemic. Fotunately, EdTech sits squarely at the confluence of these two sectors. Investors are curious to know what stocks exist therein. Boxlight Corporation is one such company. Like most small-cap stocks, they aren't a household name. The company develops and services eLearning software for the classroom. Essentially, this firm will seek to establish itself as a leader in this burgeoning sector. Their solutions include interactive digital software, 3D printing and robotics STEM-related assets, and certifications to name a few. Among them is its MimioConnect cloud platform for remote teaching and learning.In early July the company announced the appointment of two board members who should provide great direction. They have multiple decades of experience at highly respected forms in the industry. The firm also recently won two excellence awards from Tech & Learning magazine. Boxlight corporation has developed a lot of software and resources which give it many avenues to rise. BOXL shares eclipsed $4 per share in early July after having traded around $1 for the previous year. Current shares are near $2.65. Biocept Inc. (BIOC)Source: Shutterstock Given the search for a Covid-19 vaccine, this list could have easily been all biotech penny stocks. There are many exciting sectors and stocks elsewhere, but here I will focus on two of them.Biocept is a company involved with a Covid-19 vaccine. Primarily, the company deals with cancer diagnostics. The firm is undertaking a vote in order to do a reverse split of its stock to raise its price above the NASDAQ $1 minimum closing bid requirement. It will be delisted if shareholders vote against the reverse split. Clearly it is a volatile stock, yet it serves a noble cause in an important market. * 10 Gaming Stocks That Will Power Through the New Normal Biocept's involvement with a vaccine is bound to pique the interest of speculative investors. The company has assembled a Covid-19 testing kit which will be available in Q3 2020. It is clear the company is attempting to remain relevant with these two latest moves. Ampio Pharmaceuticals Inc. (AMPE)Source: Iryna Imago / Shutterstock.com Ampio Pharmaceuticals is another biotech company that is throwing its hat in the Covid-19 ring. Its primary business is the development of anti-inflammatory drugs against disorders including osteoarthritis and diabetic eye issues. Ampio Pharmaceuticals has been active in the news in the last week as it relates to the pandemic. Additionally, Ampio's drug Ampion is being touted as a treatment against inflammatory syndromes related to Covid-19. The company published a study to that effect on July 20. On July 23 it enrolled patients into its Ampion Covid-19 Program. Should the results prove positive, this stock could rocket upwards from its current $1.17 price. eMagin Corporation (EMAN)Source: Shutterstock eMagin produces OLED microdisplay technology. Its organic light emitting diodes have application in military, consumer, medical, and industrial markets. The company's share price has been marching solidly upward in a consistent channel pattern for the past year, having risen from 32 cents to roughly $1.20. Such a 300% price increase is certain to entice more investors. * 7 Cybersecurity Stocks Hard At Work While We Work From Home Unlike some other penny stocks, EMAN shares have lots of financial information with which to conduct due diligence. Lynas Corporation Limited (LYC)Source: Shutterstock Lynas Corporation is a rare earths miner. There are many such companies, but what sets Lynas apart is one powerful catalyst: its strategic partnership with the U.S. Government. The U.S. Government is worried about its ability to produce strategically important minerals. It is particularly worried about its over-reliance on China for strategic minerals used across industries. To that end it has given a contract to Lynas, an Australian company with significant operations in Malaysia. The contract will allow Lynas to begin building a heavy rare earth separation facility in Texas. When completed, the facility will be the only plant which can separate such metals outside of China. This should make clear the strategic importance of the contract. This looks like a potentially huge business with massive growth potential. Shares currently trade in the $2.50 range but jumped on the news. The Texas facility design will be ready sometime in 2021. U.S.-China tensions will dominate headlines perhaps for several decades. Thus, shares in companies like Lynas, which benefit from that reality, have great potential to grow for a long period. Ucore Rare Metals Inc. (UURAF)Source: Shutterstock Ucore Rare Metals may rise for the same reason that Lynas has risen. However, this seems to be much more speculative. Lynas is clearly a legitimate company with real operations. Ucore has much less transparency behind it. Its website is very thin on information. Nevertheless, it is a stock to keep an eye on. * 10 Gaming Stocks That Will Power Through the New Normal The company has supposedly developed a new, efficient process for separating and purifying rare earth elements. If it indeed aligns itself with U.S. national defense and can deliver, it should rise exponentially. Byrna Technologies (BYRN)Source: Shutterstock Byrna Technologies is attempting to fill a void in the self-defense market. The company produces what looks like a gun that fires bullets but actually fires chemical irritant projectiles. Basically, pepper spray paint balls. The company is trying to fill the void between close-range pepper spray, and longer-range guns which fire lethal bullets. Further, the projectiles are non-lethal and are intended to disarm attackers, or give users ample time to flee. Byrna may have cornered a large market of American self-defense consumers. Many Americans do not want the responsibility and potential liability associated with gun ownership. However, they do want to protect themselves. Byrna's products neatly provide a solution for these consumers. Therefore Byrna may have identified a lucrative revenue base. Byrna's shares have traded below 50 cents CAD since 2013. Shares only recently rose to around 1.70 CAD in June. It may be time to give a few of these penny stocks a serious look. Investors are facing volatility with most any stock. Therefore, now may be as good a time as any to take a risk. These shares are a good place to start.
- 07/31/2020
|
Coronavirus hits pockets! Salary cut of up to 35 per cent for senior employees in this airliner
- In a major development, IndiGo has confirmed that it is implementing 'deeper' pay cuts of up to 35 per cent for its senior employees in order to reduce its cash outflow amid COVID-19 pandemic.
- 07/28/2020
|
SRM University AP: Students Creating Records Across the World | Business
- Another renowned company Health Rx, A health - tech start-up from Bajaj Finserv group has offered Technical Internship with a stipend of Rs 35 thousand per month, and post that a job offer with CTC of 12 LPA to two students.
- 07/27/2020
|
Congress Has Many Ways To Boost The Economy By Getting Cash Into People’s Pockets. Which One Is Best?
- What is the best way for Congress to put Covid-19 relief into people's pockets?
- 07/24/2020
|
ICE ETF Hub Announces Launch of Innovative Custom Basket Negotiation Technology
- Intercontinental Exchange, Inc. (NYSE:ICE), a leading operator of global exchanges and clearing houses and provider of data and listings services, tod
- 07/22/2020
|
IndiGo to lay off 10% of its workforce: CEO
- "From where things stand currently, it is impossible for our company to fly through this economic storm without making some sacrifices, in order to sustain our business operations," Dutta said in a statement.
- 07/20/2020
|
Coronavirus hits employment! IndiGo CEO announces 10 pct job cut - Check what money axed employees will get
- As Covid-19 pandemic continues to hit economies across the globe, IndiGo has decided to lay off 10 per cent of its workforce.
- 07/20/2020
|
Angle Plc Announces Study: Parsortix Use in Metastatic Breast Cancer | | IT Business Net
- RESEARCH STUDY INVESTIGATES USE OF PARSORTIX LIQUID BIOPSY FOR METASTATIC BREAST CANCER PATIENTS Pilot study compared Parsortix liquid biopsy to tissue biopsy of a metastatic site Potential actionable
- 07/20/2020
|
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis) both have recommended that stockholders vote in favor of Biocept's proxy proposal to authorize a reverse stock split of Biocept's common stock, as further described in Biocept's Proxy Statement for its 2020 Annual Meeting of Stockholders. This item is Proposal 4 on the Biocept's proxy card (the "Proposal").
- 07/16/2020
|
Towards an ImageNet Moment for Speech-to-Text
- This piece will describe our pursuit of an ImageNet moment for STT
- 07/15/2020
|
Tea production may fall 13% this fiscal due to labour shortages: Report
- The report also said that as tea is a fixed cost-intensive industry, a decline in the crop will substantially increase the cost of production for the NI bulk tea industry
- 07/15/2020
|
This tax day, let's talk about why we need real tax reform
- There can be no broad racial justice without economic justice, and the tax code is an essential place to begin.
- 07/15/2020
|
Save the brew: Tourism will help Darjeeling, but the world-renowned tea shouldn't be flushed down in the process
- Darjeeling shut down and most of the first flush was lost.
- 07/12/2020
|
"Une proportion complètement inadaptée" d’emplois "sans réelle valeur ajoutée" chez les fonctionnaires polynésiens
- Dans un rapport, publié le 6 juillet, la Chambre Territoriale des Comptes dresse un constat assez rude concernant les ressources humaines de l’administration polynésienne.,
L'administration polynésienne
- 07/10/2020
|
Opinion | CTC’s ‘kadak’ command
- In locating a good CTC, you can narrow by plantation or factory, and for a slight premium in price, get an outstanding tea
- 07/10/2020
|
Coronavirus, refundable tax credits and the poverty line
- The coronavirus crisis has blocked many families living below the poverty line from their refundable earned income tax credit and even child tax credit; Congress can reverse this.
- 07/09/2020
|
Vistara Announces Pay Cut Upto 15 Percent for Employees Till December, CEO Takes 20 Percent Salary Cut
- In May, Vistara had announced that senior employees will have to go on compulsory leave without pay for up to four days per month in May and June.
- 07/01/2020
|
IndiGo, Vistara, other airlines announce fresh salary cuts, leave without pay
- Tata-Singapore Airlines joint venture Vistara announced a top-down 5-20 per cent pay cut of 40 per cent of its staff from July onwards
- 07/01/2020
|
Ircio mejorará su iluminación con nuevos proyectores y cableado
- La compra de material ha sidorealizada por algo más de 4.000 euros por Obras y Servicios y no hay un plazo cerrado para ejecutar las tareas
- 06/30/2020
|
Vistara announces 5-20 per cent pay cut for 40 per cent employees till December
- "About 60 per cent of our employees are not impacted by the pay cut," a Vistara spokesperson said.
- 06/30/2020
|
Vistara announces 5-20% pay cut for 40% employees till December
- The full-service carrier has more than 4,000 employees on its payroll. "About 60 per cent of our employees are not impacted by the pay cut," a Vistara spokesperson said.
- 06/30/2020
|
CAF firma nuevos contratos en Países Bajos, Suecia e Italia por un montante de 100 millones
- Se trata de la ampliación de dos contratos en Ámsterdam (Países Bajos) y Estocolmo (Suecia), así como uno nuevo para suministrar las unidades de metro a la ciudad de Nápoles (Italia)
- 06/30/2020
|
CAF firma nuevos contratos en Países Bajos, Suecia e Italia por un montante de 100 millones
- Se trata de la ampliación de dos contratos en Ámsterdam (Países Bajos) y Estocolmo (Suecia), así como uno nuevo para suministrar las unidades de metro a la ciudad de Nápoles (Italia)
- 06/30/2020
|
Coronavirus crisis: Vistara CEO to take 20% pay cut till December
- Vistara, which has more than 4,000 employees on its payrol, announced a pay cut between 5 to 20 per cent till December this year for around 40 per cent of its employees
- 06/30/2020
|
Vistara Announces 5-20% Pay Cut For 40% Employees Till December
- Aviation sector has been hit hard by the pandemic and all airlines in India have resorted to cost-cutting measures like pay cuts to survive the crisis.
- 06/30/2020
|
Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it has been awarded Canadian Patent 2812291, entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION. This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumor cells (CTCs), and from a biological fluid. The issuance of this patent increases Biocept's total patent awards for use in its molecular diagnostics business to 40.
- 06/30/2020
|
Vistara announces 5-20% pay cut for 40% employees till December
- Till April, Vistara's pilots were getting base flying allowance, which is a fixed component of the salary, for 70 hours per month.
- 06/30/2020
|
Covid-19 impact: Vistara CEO to take 20% salary cut till December
- The rest of Vistara's senior staff, including members of the management, will take a 15% pay cut every month.Those in mid to junior-mid levels will take 10% pay cut in this period
- 06/30/2020
|
Covid-19 impact: Vistara announces 5-20% pay cut for 40% employees till Dec
- The aviation sector has been hit hard by the pandemic and all airlines in India have resorted to cost-cutting measures like pay cuts to survive the crisis
- 06/30/2020
|
Vistara announces 5-20 per cent pay cut for 40 per cent employees till December
- Vistara on Tuesday announced a pay cut between five to 20 per cent till December this year for around 40 per cent of its employees as cash flow continues to be adversely affected due to the coronavirus pandemic.
- 06/30/2020
|
Vistara CEO to take 20% salary cut for July-December, employees to face upto 15% pay cut
- The move comes after the airline announced that it is operating with less than it is 30 per cent capacity and currently getting back to normalcy in operations and network which may take a couple of months.
- 06/30/2020
|
Vistara announces 5-20% pay cut for 40% employees till December
- About 60% of our employees are not impacted by the pay cut, Vistara said.
- 06/30/2020
|
Vistara CEO to take 20% salary cut for July-December, up to 15% pay cut for other employees
- The rest of Vistara's senior staff including members of the management will take a 15% pay cut every month, while those in mid to junior-mid levels will take 10% pay cut in this period.
- 06/30/2020
|
Rs 933 cr distributed to 28,000 MSMEs in Assam under PM's COVID-19 package: Sonowal
- The Rs 3 lakh crore package for the MSME sector, part of the Rs 20,00,000 crore economic package announced by the prime minister last month, offers collateral-free loans for small businesses Referring to the free housing scheme launched for the tea garden labourers of Assam, Sonowal said the initial 2,000 houses will be constructed for the labourers of the Assam Tea Corporation (ATC) at a cost of Rs 24 crore.
- 06/30/2020
|
Enterprise Ventures Corporation Wins Subcontract to Help Modernize the U.S. Air Force Depots’ Infrastructure
- Johnstown, PA, June 30, 2020 (GLOBE NEWSWIRE) -- Enterprise Ventures Corporation (EVC) has been awarded a competitively bid contract to provide technical...
- 06/30/2020
|
Biocept’s Covid-19 Testing Capacity Puts It at the Head of the Pack
- Unfortunately, the coronavirus isn’t going anywhere just yet, as the surge of infections in parts of the US shows no signs of slowing down. In many areas, the number of cases has continued to rise; Seven states — Arizona, Arkansas, California, North Carolina, South Carolina, Tennessee and Texas — reported the highest amount of hospitalizations since the pandemic’s onset.To help in the battle against COVID-19, diagnostics specialist Biocept (BIOC) has entered the fray. The micro-cap has manufactured 10,000 nasopharangeal swab collection kits, which will be available by 3Q to conduct PCR testing for COVID-19 in California.Maxim analyst Jason McCarthy believes “Biocept may be in the right place at the right time.”“The availability of Biocept's collection kits comes at a crucial time when California is seeing a surge in COVID-19 cases as well as undergoing reopening. With the capacity to perform up to 2,000 tests per day, Biocept could play a role in the testing regimen for California,” said McCarthy.As far as the commercial opportunity is concerned, taking into consideration the $100 reimbursement from the Centers for Medicare & Medicaid Services (CMS) for every test in labs with high throughput testing technology - for which Biocept qualifies - the 10,000 kits could represent revenue of $1 million. However, Biocept could potentially increase the testing capacity by a large margin.“The number is far below Biocept's laboratory capacity,” McCarthy said. The 5-star analyst added, “Which stands at 300-2,000 tests per day, meaning the number could increase significantly. We expect Biocept to continue to build-out its sample collection kit production.”To this end, McCarthy keeps a Buy rating on Biocept shares along with a $1 price target. Investors will be looking at a 57% gain, should McCarthy’s call play out over the next 12 months. (To watch McCarthy’s track record, click here)Over the last three months, only one other analyst has posted a review regarding Biocept’s prospects. The additional Buy provides the micro-cap with a Moderate Buy consensus rating, while the average price target of $1.53 suggests potential upside of a hefty 120%. (See Biocept stock-price forecast on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/27/2020
|
Opinion | Tea from Buddha’a land
- Artisanal tea from Bihar is grown on river-fed land, cultivated naturally and offers sustenance to the local community
- 06/26/2020
|
8 cosas que debes saber para presentar impuestos antes de la fecha límite
- En los próximos días, muchas personas reunirán sus documentos para presentar sus impuestos del 2019. Aunque la fecha límite para presentar impuestos se extendió hasta el 15 de julio, ese día ya se …
- 06/25/2020
|
UPASI TEA RESEARCH FOUNDATION Tea Research Institute Nirar Dam PO, Valparai – 642 127, Coimbatore Dist., India
- RejoinderUPASI TEA RESEARCH FOUNDATION REJOINDER TO THE ARTICLE TITLED “‘RUDE FOOD BY VIR SANGHVI: TEA TALES PUBLISHED IN THE HINDUSTAN TIMES – DATED 13TH JUNE 2020.
- 06/25/2020
|
SBI offers jobs with salary up to Rs 99 lakh, Dearness Allowance, HRA, PF, CPF, Medical; Details here
- SBI SO Recruitment 2020 Notification, Last Date, Salary: The State Bank of India recently issued notifications for hiring candidates as Specialist Officers on regular as well as contractual basis.
- 06/24/2020
|
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed care provider agreement with Medical Cost Containment Professionals, LLC (MCCP) to process out-of-network claims for Biocept's Target Selector™ liquid biopsy testing. MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide.
- 06/24/2020
|
Cape Coast Technical University programmes and admissions
- Are you looking for a great place to study, but you do not know how to make the best option? CAPE COAST TECHNICAL UNIVERSITY is the best option for you now.
- 06/24/2020
|
The CAO of Flex (NASDAQ: FLEX) is Selling Shares - Markets
- Yesterday, the CAO of Flex (FLEX – Research Report), David Bennett, sold shares of FLEX for $19.61K. In addition to
- 06/24/2020
|
Rare Disease Diagnostics: Assessment of Technologies and Global Markets with Profiles of 95+ Industry Players - ResearchAndMarkets.com
|
Red Hat Helps CO-OP Enable Faster, More Flexible Application Development with Red Hat OpenShift
- JCIF selects Red Hat OpenShift as the Kubernetes backbone for the company's online policyholder portal.
- 06/23/2020
|
After leaving job, how long will my EPF account earn interest? Will interest stay tax-free?
- Despite the tax on the interest, EPF continues to have the highest returns among small saving schemes. So it makes sense to make small periodic withdrawals to ensure that the account does not become inoperative.
- 06/22/2020
|
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 (COVID-19) for physician ordering. Collected specimens will be shipped overnight to Biocept's high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering physicians in an estimated 24 to 48 hours.
- 06/22/2020
|
The diplomatic dance for the horseshoe table
- With multilateralism under pressure, particularly as a result of Covid-19, UNSC, too, has its challenge set. India’s term on UNSC will also coincide with India hosting Brics (Brazil, Russia, India, China and South Africa) and G-20 summits. India should use the opportunity to push its case on Security Council reform to open up the horseshoe table that seats the UNSC.
- 06/20/2020
|
We'd like to be seen as a full service new-age private bank: CSB Bank chief
- In a Q&A, C V R Rajendran, MD & CEO, CSB Bank Ltd, dwells on how the lender turned around in FY20, after several years of losses
- 06/20/2020
|
Biocept (NASDAQ:BIOC) Trading 47.2% Higher
- Biocept Inc (NASDAQ:BIOC)’s share price traded up 47.2% during trading on Thursday . The company traded as high as $0.98 and last traded at $0.95, 178,491,773 shares traded hands during trading. An increase of 795% from the average session volume of 19,951,064 shares. The stock had previously closed at $0.65. Several research analysts have weighed […]
- 06/20/2020
|
Assessment of COVID-19's Effect on Breast Cancer Liquid Biopsy Testing Devices Market 2020-2024 | Enhanced Emphasis on Personalized Medicine to Augment Growth | Technavio
- The Global Breast Cancer Liquid Biopsy Testing Devices Market will grow by USD 479.83 mn during 2020-2024
- 06/19/2020
|
Eliminan la limitación temporal de 71 plazas de aparcamiento de movilidad reducida
- El Consistorio mantendrá la restricción de 2 horas como máximo en otras 11 plazas «que dan servicio a edificios públicos o son de zona azul»
- 06/18/2020
|
Pilots bear the brunt of the pandemic as airlines embark on a cost-cutting spree
- Indian airlines have cut salaries, allowances and sent pilots on leave without pay to lower costs in the wake of covid-19.A senior pilot is now paid a gross salary of ₹1.25 lakh per month compared to a pre-covid salary of ₹6.5 lakh
- 06/18/2020
|
Using Reverse Innovation to Fight Covid-19
- Global problems call for global solutions.
- 06/17/2020
|
Paper Boat backer A91 Partners to invest ₹125 crore in Pushp Spices
- The A91 Partners' investment in Pushp is the first fund raise for the company.The capital will be used for expanding and deepening the company's distribution network, expanding its sales team
- 06/17/2020
|
SBI Recruitment: Caution! Beware of fake selection letters - Must know information for State Bank of India jobs aspirants
- India's largest lender, State Bank of India (SBI) on its official website, sbi.co.in has uploaded a CAUTION letter about "FAKE SELECTION LETTERS /LISTS SENT BY FRAUDSTERS IN THE NAME OF SBI".
- 06/17/2020
|
How salary cut impacts your PF corpus and gratuity
- Most of the retirement benefits such PF contribution and gratuity are calculated on the basis of basic salary and dearness allowance. Therefore, a cut in salary will have an impact on these benefits.
- 06/17/2020
|
The technology allowing hospital consultants to do ward rounds from home
- It is just one of many digital projects which are being trialled or gone live in the NHS since the start of the coronavirus crisis
- 06/15/2020
|
With work from home comes pay for home
- Sectors such as IT and IT services, BFSI are introducing more relevant salary components.
- 06/15/2020
|
Rules and openings for every major high street in Cornwall
- Finally, it's #IAmOpen day - and hundreds of shops are getting ready to welcome back customers
- 06/14/2020
|
Rude food by Vir Sanghvi: Tea tales
- No matter how much tea it produces, India does not drink real tea itself. And now there are concerns about fluoride and pesticide levels.
- 06/13/2020
|
COVID-19 அறிகுறியாக திடீரென சுவை இழப்பு, வாசனையின்மை அடங்கும்...
- திடீரென சுவை இழப்பு, வாசனையின்மை ஆகியவை கோவிட் -19 சோதனை அளவுகோல்களில் சேர்க்கப்படலாம் என அரசு அறிவிப்பு..!
- 06/12/2020
|
Colombia protests over attacks on workers’ rights
|
Money Matters: Learning from an Accounting Professional
- One of your neighbors posted in Neighbor Posts. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 06/11/2020
|
This SBI job offers a huge annual salary package of Rs 1 crore - Check full recruitment details from official notification here
- State Bank of India has invited applications from eligible candidates for the post of Chief Financial Officer (CFO) on contract basis at a salary package of Rs 1 crore, three times more than its chairman's.
- 06/11/2020
|
Road Freight Market In India, Road Freight Industry In India
- The report covers India Digital Freight Aggregators Market, Truck Small Fleet Operators India, India Medium Fleet Operators Market.
- 06/11/2020
|
India Road Freight Market, India Road Freight Industry
- The report covers India Road Freight Market, India Road Freight Industry, Road Freight Market Research Report, Industry Research Report.
- 06/11/2020
|
SBI looking for new CFO, offering package up to Rs 1 crore
- The person who bags the job will be getting three times more than that of the chairman.
- 06/11/2020
|
SBI looking for CFO, annual package up to Rs 1 crore, three times more than bank Chairman’s CTC
- The SBI chairman Rajnish Kumar was Rs 29.5 lakh in 2018-19, an SBI annual report had said.
- 06/11/2020
|
SBI invites applications for CFO post; offers annual package of Rs 1 crore
- Earlier, the CFO used to be from the bank's senior management. Currently, the CFO position is held by Chalasani Venkat Nageswar, a Deputy Managing Director of the bank.
- 06/10/2020
|
John Cena donates $1m to Black Lives Matter after widespread protests
- The West Newbury, Massachusetts native tweeted: 'Very happy to join #BTSARMY in efforts to match BTS' tremendous donation #ARMYMatch1M.'
- 06/10/2020
|
SBI invites applications for post of CFO; offers annual salary of Rs 1 cr
- This is for the first time, the bank is recruiting the CFO from outside its experienced talent pool of top management
- 06/10/2020
|
In a First, SBI Invites Applications for CFO Post, Offers Annual Package of Rs 1 Crore
- As per the recruitment notice, the position is for a contract period of three years and the annual CTC (cost to company) and perks would be Rs 75 lakh to Rs 1 crore.
- 06/10/2020
|
Attention job seekers: SBI invites applications for CFO post; offers annual package of Rs 1 crore
- The country's largest lender State Bank of India has invited applications from eligible candidates for the post of Chief Financial Officer (CFO) on contract basis at a salary package of Rs 1 crore, three times more than its chairman's.
- 06/10/2020
|
SBI looks to hire CFO, data protection officer
- For the CFO's role, SBI is looking to hire a chartered accountant with minimum 15 years of experience for a period of 3 years.The bank will offer an annual cost to company (CTC) in the range of ₹75 lakh to ₹1 crore
- 06/09/2020
|
Pressure Mounts on APC to Disqualify Godwin Obaseki from Edo State Guber Race | BizWatchNigeria.Ng
- The intrigues over who clinches the ticket of the All Progressives Congress (APC) for the September governorship election in Edo State deepened
- 06/09/2020
|
CIRI Announces Nathalie Megann as New Board Chair and Elects New Directors
- CIRI announces the election of Nathalie Megann, CPIR, ICD.D (Chair), Greg Blazina, David S. Frost and Lisa Greatrix to the Board of Directors.
- 06/09/2020
|
BUY ALERT: Canadian Tire (TSX:CTC.A) Stock Just Popped 70%
- Canadian Tire (TSX:CTC.A) stock was pummeled from the COVID-19 fallout, but in recent weeks, shares have rocketed higher by nearly 70%.
- 06/08/2020
|
Los Reyes visitan el Centro de Transportes de Coslada
- Recorrieron el Centro de Distribución de Alimentación de El Corte Inglés y Sending
- 06/05/2020
|
Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. The move is expected to be completed by 2020 year end.
- 06/05/2020
|
COVID-19 fallout: Amara Raja Group announces pay cut to employees
- The company however, said the reduced amount will be paid back to the employees under 'Business Performance Linked Pay' (BPLP) in the next financial year if the businesses recover and get back to the required levels of performance.
- 06/03/2020
|
GVK Group cuts salaries by up to 30% from May as Covid-19 impacts business
- The diversified group, which is into energy, resources, airports, transportation, hospitality and life sciences sectors, has around 1,800 workforce
- 06/03/2020
|
GVK Group cuts salaries up to 30 pc from May amid coronavirus pandemic
- GVK Group has slashed salaries of its staff across companies by up to 30 per cent from May amid the coronavirus pandemic, which has significantly impacted markets and businesses due to a total shutdown of nearly two months, a source said on Wednesday
- 06/03/2020
|
GMR Group cuts employees' salary by up to 50% due to COVID impact
- Battling against challenges in the wake of the COVID-19 pandemic, diversified conglomerate GMR Group has revised downwards employees' salary by up to 50 per cent with effect from May, a source said.
- 06/03/2020
|
GMR Group cuts employees' salary by up to 50% due to COVID impact
- The Bengaluru-based infrastructure major has presence in roads and highways, energy and airport sectors.
- 06/02/2020
|
Opinion | What expensive workers in their 50s need to do
- Those in their 50s need a financial and work strategy to fight the effects of covid-19
- 06/02/2020
|
CTC Global Names Kevin Corbalis Vice President, Engineering and Product Development
- CTC Global Names Kevin Corbalis Vice President, Engineering and Product Development
- 06/02/2020
|
Yes Bank leadership team to earn up to 30% of FY21 remuneration in variable pay
- Yes Bank did not specify as to what is the current level of variable pay for its leadership team
- 05/31/2020
|
EPF contribution at 10% likely to push up your take home by only 1-2%
- As per the analysis, a 4% gross increase of basic wages due to reduction in EPF contribution to 10% for both employers and employees for May, June and July 2020 may not make a material difference to an employee.
- 05/30/2020
|
Ministry of Health launches app for communities to send alerts about COVID-19 suspects
- Kampala, Uganda | THE INDEPENDENT | The Ministry of Health has launched a mobile app which can be used by people who develop symptoms of the coronavirus (COVID-19) or suspected to be infected to alert the surveillance officials in the communities. The app dubbed ‘Call The Clinic’ short coded as MOH – CTC uses digital …
- 05/29/2020
|
Biocept Shares Tick Higher Following Co. Tweet '...a new 15-minute scan, known as the prostagram, may replace rectal examinations for detecting #prostatecancer...'
|
Biocept Announces Data For Cerebrospinal Fluid At ASCO
|
Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the presentation of data affirming the ability of its Target Selector™ platform to identify potentially actionable mutations in the cerebrospinal fluid of patients whose cancer has metastasized to the central nervous system. The data were presented today by Kevin Kalinsky, MD, MS, associate professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, an oncologist at New York-Presbyterian/Columbia University Irving Medical Center, and the study's principal investigator, in a poster at the American Society for Clinical Oncology (ASCO) 2020 Virtual Scientific Program. The abstract is available here.
- 05/29/2020
|
EPF Contribution: Why Employees And Employers May Want To Stick To 12%?
- The Employees Provident Fund Organisation (EPFO) has now provided clarification on the reduction of contribution towards EPF (Employees Provident Fund) for the months of May, June and July as part of the governments Atmanirbhar Bharat Package. The pension fund manager has said that you, as well as your employer, hav
- 05/29/2020
|
United Kingdom Childcare Market Report 2020 - Market Insights, Politics & Regulation, Payors, Staffing, Major Providers, Investors, and Future Potential - ResearchAndMarkets.com
|
Voluntary provident fund: Investing, contribution, interest rate and other things to know
- If you are planning to invest in the Voluntary Provident Fund (VPF), here are the answers of the some the commonly asked questions about it.
- 05/28/2020
|
Shares of several healthcare companies are trading higher in sympathy with the overall market as equities rally on coronavirus vaccine hopes as well as a pickup in economic activity as some US states reopen businesses.
|
Biocept Inc. (NASDAQ: BIOC) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Biocept Inc. - BIOC stock
- 05/26/2020
|
Income Tax Implication Will Stay The Same If CTC Does Not Change Despite Salary Cut
- Due to the COVID-19 outbreak, business and jobs have been impacted. If you have also been informed of pay cut at your place of work, you should make sure that such the change has been reflected in your cost-to-company (CTC) as well. This is because your income tax liability will not change if your CTC does not reflect
- 05/26/2020
|
WWE legend John Cena ‘donates’ to Shad Gaspard’s family after star tragically drowned at sea
- John Cena reportedly gave AU$60,800 to Shad Gaspard’s devastated family after the wrestler tragically drowned in California.
- 05/26/2020
|
4 Indian tea brands that are disrupting a multimillion-dollar industry
- India is a predominantly tea-drinking nation, and, with its swathes of tea-growing valleys, is eyeing the top-spot for quality tea production in the world. Homegrown brands have been helping preserve the rich heritage of tea drinking in the country.
- 05/26/2020
|
Reduced EPF contribution: How you will get impacted?
- The liquidity crunch caused by the lockdown across industries has implored the Government of India to announce a number of reliefs with respect to the provident fund obligation of employers.
- 05/24/2020
|
EPFO Clarifies On Employee CTC & Pension After EPF Rule Change
- soon after the rule of lower contribution to EPF account was notified, the retirement fund body EPFO released frequently asked questions or FAQs that aimed at providing clarity on the statutory reduction in contribution rate to EPF account by both the employer and employee.
- 05/23/2020
|
Lower PF contribution not mandatory; EPFO clarifies on CTC, pension of employee
- The lower contribution is not mandatory for both the employer and the employee..Employers who are following the CTC model will have to compensate their employees.
- 05/23/2020
|
TPC Estimates The HEROES Act Would Substantially Cut Individual Income Taxes
- The House-passed HEROES Act would cut taxes for nearly all households, and most benefits would go to low- and moderate-income tax filers.
- 05/22/2020
|
Got a pay cut? You may still be taxed on your original CTC
- If a pay-cut is not reflected in the components of your salary, you may still be taxed on your original CTC.
- 05/21/2020
|
Reduced EPF contribution: 16 questions answered by EPFO
- The reduction in EPF contribution to 10 per cent was announced by Finance Minister Nirmala Sitharaman as a part of the Atmanirbhar Bharat Package to provide some relief to employers and also to increase the take-home pay of the employees.
- 05/20/2020
|
New EPF Rule: How Will Your Salary Change From May?
- Now as there will be a total 20% contribution i.e. 10% each by the employee and employer to the EPF account, the 2% reduced contribution by the employee shall be paid out as increased take home pay to the employee.
- 05/20/2020
|
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
|
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air" hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 12:00 p.m. Eastern time (9:00 a.m. Pacific time).
- 05/20/2020
|
Explained: What more Basic + Dearness Allowance you may get in next month salary and tax liability
- In a case where the CTC does not include the employer’s contribution, then the take-home salary increases by 2 per cent of the basic salary minus TDS.
- 05/19/2020
|
Investment in NPS via this route can help you save tax in new tax regime
- Investment in Tier-I account of NPS via your employer allows you to claim a deduction from your gross total income under the Income-tax Act even under the new lower tax regime. Here's all you need to know about it.
- 05/19/2020
|
Global Circulating Tumor Cell (CTC) Market Size, Share & Trends Analysis Report 2020 - ResearchAndMarkets.com
|
IIM-Ranchi concludes final placement with avg annual pay of Rs 15.11 lakh
- The highest international compensation offered stood at 59.37 lakh per annum and the highest CTC offered to the MBA-HR batch stood at 26.50 lakh per annum
- 05/16/2020
|
NTUC honours 29 organisations with May Day Awards
- SINGAPORE - Cleaning staff at Copthorne King's Hotel used to take about two hours to clean and polish the glass panels at the hotel's lobby.. Read more at straitstimes.com.
- 05/16/2020
|
CPL: Chris Gayle stands by his 'worse than coronavirus' remark on Sarwan
- The self-styled 'Universe Boss' admitted, in a statement issued by CPL Technical Committee chief, that his description of Sarwan was 'damaging Cricket West Indies, and to CPL tournament and its brand'
- 05/16/2020
|
Biocept Highlights Release of its Target Selector BRAF Kit For Clients' Use In Their Own Laboratories
|
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of a Target Selector™ molecular assay research-use-only (RUO) kit for the detection of BRAF mutations. Biocept's molecular assay kits offer superior sensitivity compared with next generation sequencing (NGS) panels for the detection of biomarkers of key oncogene mutations from a blood sample.
- 05/14/2020
|
Cut in employer's EPF contribution may mean net loss for the employees
- Centre has reduced both employer and employee contribution in the EPF account as a Covid-19 measure.
- 05/14/2020
|
Ibovespa fecha em queda de 0,13%, a 77.772,20 pontos
- O Ibovespa encerrou o pregão desta quarta-feira (13) em queda de 0,13%, a 77.772,20 pontos .Clique aqui para saber mais.
- 05/13/2020
|
Biocept Q1 EPS $(0.110) Up From $(0.610) YoY, Sales $1.447M Miss $1.910M Estimate
|
Biocept Reports First Quarter 2020 Financial Results
- Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its business progress.
- 05/13/2020
|
CVM aceita termo de compromisso com diretor da JBS (JBSS3)
- A CVM aceitou, na última terça-feira (12), propostas de termo de compromisso referentes aos executivos de Relações com Investidores da JBS.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
UWM now offering mortgage interest rates as low as 2.5% - HousingWire
- The average interest rate for a 30-year fixed mortgage currently sits at 3.25%, but UWM customers could soon receive an interest rate well below 3%.
- 05/12/2020
|
Massive House Bill Includes New & Improved Stimulus Checks, Expanded Jobless Benefits And Tax Relief
- House Speaker Nancy Pelosi announced a new COVID-19 economic relief proposal. The bill is known as the Health and Economic Recovery Omnibus Emergency Solutions Act, or HEROES Act.
- 05/12/2020
|
Itochu Corp (ITOCF) Management on Full Year 2020 Results - Earnings Call Transcript
- Itochu Corp (OTCPK:ITOCF) Full Year 2020 Earnings Conference Call May 08, 2020 3:00 AM ET Company Participants Yoshihisa Suzuki – President and Chief Operating
- 05/11/2020
|
Canadian Tire Corporation, Limited (CDNTF) CEO Gregory Hicks on Q1 2020 Results - Earnings Call Transcript
- Canadian Tire Corporation, Limited (OTC:CDNTF) Q1 2020 Earnings Conference Call May 07, 2020, 08:00 AM ET Company Participants Gregory Hicks - President and CEO
- 05/10/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Canadian Tire : Announces Election of Directors | MarketScreener
|
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three months ended March 31, 2020 after the market closes on Wednesday, May 13, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
- 04/29/2020
|
Immunomedics Gets Early FDA Approval - Path To Profitability Still Treacherous
- New CEO paired with an unproven marketing team. US launch strategy still a moving target. Major competitive threat looming. Valuations stretched compared to mos
- 04/28/2020
|
Biocept Reports CE-IVD Mark For Its Target Selector EGFR Molecular Assay Kit In Europe
|
Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the award of CE (Conformité Européene)-IVD Mark for its Target Selector™ molecular assay EGFR Kit. The CE Mark confirms that the Company's Target Selector™ kit products meet the requirements of the European In-Vitro Diagnostic Devices Directive (98/79/EC) and allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies.
- 04/28/2020
|
Lockdown advice for struggling self-employed people in Plymouth
- Citizens Advice Plymouth seeing stark rise in calls to phone lines and webchats over coronavirus employment issues
- 04/23/2020
|
What if we can’t eradicate COVID-19?
- What if, despite our efforts, the novel coronavirus stubbornly continues to spread in Australia at a low but appreciable rate. Should we continue to impose economically and socially stifling lockdowns until a vaccine is developed? Should we lift the lockdowns and let the virus spread? Now is the time to think about what to do if the virus proves to be ineradicable in the near term.
- 04/21/2020
|
Biocept Highlights Launch Of Research-Use-Only Kits Allowing Labs To Utilize Co.'s Target Selector Assay Kits To Detect, FFPE Tissue, ctDNA
|
Biocept Launches Line Of Molecular Assay Kits For Detection Of Key Oncogene Mutations Based On Its Proprietary Target Selector Technology Validated For Use In Both Tissue And Blood Samples
|
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits that can allow molecular laboratories around the world to utilize Biocept's Target Selector™ molecular assay kits to detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies.
- 04/20/2020
|
How the old tax regime serves the double benefit of tax-saving and financial well-being
- It is universally accepted that tax breaks on investments nudge people to save more. The new tax regime has taken away the incentive to save. The deductions ensure financial wellbeing of taxpayers. Do you know the role they plan in your financial plan?
- 04/20/2020
|
Biocept Prices 22.3M Common Stock Offering At $0.46/Share
|
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on April 14, 2020 it entered into a securities purchase agreement with several institutional investors for the issuance and sale of 22,300,000 shares of its common stock at a price of $0.46 per share, for aggregate gross proceeds of approximately $10.3 million, in a registered direct offering.
- 04/14/2020
|
ICANN asks registrars to crack down on scam coronavirus websites
- It doesn’t have regulatory authority, so it can’t do much, but the hundreds of registrars it authorizes can and should.
- 04/14/2020
|
Mid-Day Market Update: Dow Falls Over 500 Points; SCWorx Shares Spike Higher
- Midway through trading Monday, the Dow traded down 2.25% to 23185.53 while the NASDAQ fell 0.89% to 8,081.03. The S&P also fell, dropping 1.95% to 2,735.29.
The U.S. is the...
- 04/13/2020
|
Mid-Morning Market Update: Markets Open Lower; OPEC+ Reaches Deal To Cut Oil Production
- Following the market opening Monday, the Dow traded down 1.35% to 23,399.06 while the NASDAQ fell 0.42% to 8,119.59. The S&P also fell, dropping 1.24% to 2,755.34.
The U.S. is...
- 04/13/2020
|
Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics
- As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and...
- 04/13/2020
|
20 Healthcare Stocks Moving In Monday's Pre-Market Session
- Gainers
• Biocept, Inc. (NASDAQ:BIOC) stock moved upwards by 55.72% to $0.56 during Monday's pre-market session.
• BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock...
- 04/13/2020
|
30 Stocks Moving in Monday's Pre-Market Session
- Gainers
Biocept, Inc. (NASDAQ: BIOC) shares rose 68.3% to $0.5997 in pre-market trading. Biocept disclosed that it has verified a COVID-19 molecular diagnostic test.
U.S. Well...
- 04/13/2020
|
Biocept shares are trading higher after the company said it has a coronavirus test and will begin accepting physician orders this week.
|
Biocept to Begin COVID-19 Testing
- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020.
- 04/09/2020
|
